plovamer acetate

Plovamer acetate is a second-generation synthetic random copolymer of four amino acids (L-glutamic acid, L-alanine, L-tyrosine, and L-lysine) designed as an immunomodulatory peptide for the treatment of autoimmune diseases. It was rationally engineered to improve upon glatiramer acetate by optimizing the ratio and sequence of its constituent amino acids. Plovamer acetate acts primarily as a major histocompatibility complex (MHC) class II modulator; it competitively binds to MHC II with higher affinity than glatiramer acetate and induces a T-helper 2 (Th2)-like immune response. This mechanism is intended to reduce inflammatory activity in diseases such as multiple sclerosis by shifting immune responses away from pro-inflammatory pathways. The drug was developed by Peptimmune and EMD Serono for indications including relapsing-remitting multiple sclerosis (RRMS), Crohn's disease, rheumatoid arthritis, and uveitis but development has been discontinued in all indications[2][3][7].

Other names

plovamerPI-2301PI2301PI 2301CO-14CO14CO 14